Carcinogenesis Advance Access originally published online on August 31, 2006
Carcinogenesis 2007 28(2):372-377; doi:10.1093/carcin/bgl153
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Association of p73 G4C14-to-A4T14 (GC/AT) polymorphism with breast cancer survival
Breast Center, Beijing Cancer Hospital Peking University School of Oncology, 100036, Beijing, P. R. China
1 Department of Pathology, Beijing Cancer Hospital Peking University School of Oncology, 100036, Beijing, P. R. China
*To whom correspondence should be addressed. Tel: +86 10 88196362; Fax: +86 10 88196362; Email: zlxyt2{at}bjmu.edu.cn
p73 gene shares structural and functional similarities to p53, and plays an important role in modulating cell-cycle arrest and apoptosis. A common non-coding polymorphism of exon 2 of the p73 gene (designated as GC/AT) may affect gene expression, thus, it may lead to functional significance. The correlation of this polymorphism with breast cancer survival has not been investigated. In this study, by using genomic DNA p73 GC/AT polymorphism was detected by PCR-SSCP in 526 breast cancer patients with a median follow-up of 7.3 years. Among the 526 breast cancer patients, 4% of the patients were homozygous for the AT/AT genotype, 39% were heterozygous GC/AT and 57% were homozygous for the GC/GC genotype. We found that patients with the GC/GC genotype had a significantly worse clinical outcome than did patients with the AT Variants (AT/AT or GC/AT genotype) (5-year disease-free survival, 74.2 versus 95.0 or 84.1%, P = 0.02; 5-year overall survival, 78.9 versus 95.0 or 87.5%, P = 0.01, respectively). As compared with the GC/AT and AT/AT genotypes, the GC/GC genotype remained an independent prognostic indicator of disease-free survival (HR 1.82, P = 0.003) and overall survival (HR 1.99, P = 0.004) in multivariate analysis. Our results suggest that the GC/GC genotype is significantly associated with poor prognosis in breast cancer and raise the possibility that analysis of p73 polymorphism may provide useful prognostic information for breast cancer patients. Additional independent studies are needed to confirm these findings.
Abbreviations: PCR-SSCP, polymerase chain reaction single-strand conformation polymorphism; ER, estrogen receptor; PR, progesterone receptor; DFS, disease-free survival; OS, overall survival
Correspondence may also be addressed to Jiyou Li. Email: lijiyou{at}263.net
Received May 8, 2006; revised July 24, 2006; accepted August 18, 2006.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
M. Udler, A.-T. Maia, A. Cebrian, C. Brown, D. Greenberg, M. Shah, C. Caldas, A. Dunning, D. Easton, B. Ponder, et al. Common Germline Genetic Variation in Antioxidant Defense Genes and Survival After Diagnosis of Breast Cancer J. Clin. Oncol., July 20, 2007; 25(21): 3015 - 3023. [Abstract] [Full Text] [PDF] |
||||
